



/

/

-

A59/11

-

-

.

-

-

.

-

.

-

-

.

.

/

.

.

.

/ / /

/

-

-

-
-
-
(/ -)

-

:

-

()

/

. /

()

()

:

-

()

()

()

()

-


.....		
.....		
.....	:	-
.....		-
.		-
.....		- -
.....		- -
.....		- -
.....		- -
.....		-
.....		- -
.....		- -
.....		- -
.....		- -
.....		- -
.....		- -
.....		- -
.....		- -
.....		-
.....		-
.....		-
.....		-
.....		-
.....	:	-
.....		
.....		-
.....		-
.....		- -
.....		- -
.....		- -
.....		- -
.....		- -
.....		- -

.....	-
.....	- -
.....	- -
.....	-
.....	- -
.....	- -
.....	- -
.....	- -
.....	-
.....	- -
.....	- -
.....	- -
.....	- -
.....	- -
.....	- -
.....	- -
.....	-
.....	- -
.....	- -
.....	- -
.....	-
.....	- -
.....	- -
.....	-
.....	-
.....	-
.....	-
.....	-
.....	-

()

-

:



" " •

" "

.() .()

()

:

			()
()	:		
	:		
	:		
()	:		
	:		
	:		
()	:	(-)	
(())	:		
()	:		
	:		
()	:		()
	:		
()	:		
()	:		

-

--

.
. .
.

.(

)

.
--

.

.()

.(-)

-

.()

.()

.CD4

.()

- -

.()

)

-

.()

-

-

(

.(-)

- -

(/)

()

- -

)

(

:()

- -

)

.()

(

.()

)

(

)

(

:

.

)

(

:

-

-

-

:

.

.

.

.

.

()

-
-

:

-
-
-
-

:

:

:

()

-
-
-
-
-

Paris Declaration on Aid Effectiveness: Ownership, Harmonisation, Alignment, Results and Mutual Accountability. Paris, March 2005.

-

-

-

-

()

-

-

-

:

•

:


•

: -
-

.()

(.())

()



-
-
-
-
-
-
-
-
-
-

()

.()

.()


()

.()

:()

-
-
-
-
-

-



()

.()

.()

:

. ()

)

(

-
-
-

()

(

)

. ()

()

.()

-

.()

.()

-

()

-

.. "

- -

.

.

)

(

.

:

-

-

:

-

-

-

-

-

-

.

:

)

.

(

)

(

.

.

.

.

(mystery clients)

()

- .
.
- -

.
:
) -
() -
() -
() -
) -
() -

-
--

.() , ,

.()

-
-

()

-

-

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

)

.(

.

.

.

.

.

.

.()

.

.

)

(

.() .()

Bacterial vaginosis

.()

PID

)

(

.()

.()

.()

.()

" "

.()

" "

.()

--

" - " .() - -

- -

-
-
-
-

()

()

)

(

- -

)

(

--

()

)

.(

(
.()

)

(

)

()

.()

()

.()

)
()
()
()
()
()

.

()

.()

.

.

.

--

.

.

.

.

.

.

.

.

.

.

()

--

()

- -

) ()

.(
:

) .

.(

.

)

.

.(

.

)

.(

:

.

-

-
-
-
-
-
-
-
-
-

-

.() .

"

.

"

.

)

.(

.

--

:

-

-

-

-

-

() () () ()
.() () .())
.())

:

-

-

-

-

:

-

--

()

•

:

-

-

.()

" "

•

.

-

•

/

•

.

•

()

-	-	-
-	-	-
-	-	-
-) -	-
-	(-
-	-	-
-	-	-

• • •		• • • • • • •
• • • •	()	• • • • • • • • • • (PDAS)
•	()	• • • • • • (PDAS)
•		•
•		• •

:

-

-

()
:

)

(

-

-

-

.()

-

:

-

-

-

-

-

-

:

-

-

-

-

()

()

-

1. Holmes K et al., Eds. *Sexually transmitted diseases*, 3rd ed. New York, McGraw-Hill, 1999, xxi.
2. *Global prevalence and incidence of curable STIs*. Geneva, World Health Organization, 2001 (WHO/CDS/CDR/EDC/2001.10).
3. Mayaud P, Mabey D. Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges. *Sexually Transmitted Infections*, 2004, 80:174-182.
4. Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. *Perspectives on Sexual and Reproductive Health*, 2004, 36:6-10.
5. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. *Herpes*, 2004, 11(Suppl. 1):24A-35A.
6. Pujades Rodriguez M et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. *AIDS*, 2002, 16:451-462.
7. Ferlay J. Cancer incidence, mortality and prevalence worldwide. Lyon, International Agency for Research on Cancer, 2004 (GLOBOCAN 2002. IARC Cancer Base No. 5. version 2.0).
8. *State of the art of new vaccines: research and development*. Geneva, World Health Organization, Initiative for Vaccine Research, 2003.
9. *The world health report 2004 – Changing history*. Geneva, World Health Organization, 2004.
10. *Hepatitis B*. Geneva, World Health Organization, 2002 (WHO/CDS/CSR/LYO/2002.2).
11. Montesano R. Hepatitis B immunisation and hepatocellular carcinoma: The Gambia Hepatitis Intervention Study. *Journal of Medical Virology*, 2002, 67:444-446.
12. Chang MH et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. *JAMA*, 2000, 284:3040-3042.
13. *AIDS epidemic update: December 2005*. Joint United Nations Programme on HIV/AIDS and World Health Organization, 2005 (UNAIDS/05.19E).
14. *Consultation on STD interventions for preventing HIV: what is the evidence?* Geneva, Joint United Nations Programme on HIV/AIDS and World Health Organization, 2000.
15. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2. Seropositive persons: a meta-analysis. *Journal of Infectious Diseases*, 2002, 185:45-52.
16. Nagot N et al. *Effect of HSV-2 Suppressive therapy on HIV-1 genital shedding and plasma viral load: a proof of concept randomized double-blind placebo controlled trial (ANRS 1285 Trial)*. Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, abstract 33LB, 2006.
17. Hayes RJ, Schulz KF, Plummer FA. The cofactor effect of genital ulcers in the per-exposure risk of HIV transmission in sub-Saharan Africa. *Journal of Tropical Medicine and Hygiene*, 1995, 98:1-8.

18. Cohen MS et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. *Lancet*, 1997, 349:1868–1873.
19. Buchacz K et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. *AIDS*, 2004, 18:2075–2079.
20. Simms I, Stephenson JM. Pelvic inflammatory disease epidemiology: what do we know and what do we need to know? *Sexually Transmitted Infections*, 2000, 76:80–87.
21. Westrom L et al. Incidence, prevalence and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. *American Journal of Obstetrics and Gynecology*, 1980, 138:880–892.
22. Schulz KF, Cates W Jr, O'Mara PR. Pregnancy loss, infant death, and suffering: legacy of syphilis and gonorrhoea in Africa. *Genitourinary Medicine*, 1987, 63:320–325.
23. Gutman L. Gonococcal diseases in infants and children. In: Holmes K et al., eds. *Sexually transmitted diseases*, 3rd ed. New York, McGraw-Hill, 1999:1145–1153.
24. Laga M, Meheus A, Piot P. Epidemiology and control of gonococcal ophthalmia neonatorum. *Bulletin of the World Health Organization*, 1989, 67:471–478.
25. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. *Bulletin of the World Health Organization*, 2001, 79:214–221.
26. Schaller U, Klauss V. Is Credé's prophylaxis for ophthalmia neonatorum still valid? *Bulletin of the World Health Organization*, 2001, 79:262–266.
27. Schmid G. Economic and programmatic aspects of congenital syphilis prevention. *Bulletin of the World Health Organization*, 2004, 82:402–409.
28. Terris-Prestholt F et al. Is antenatal syphilis screening still cost effective in sub-Saharan Africa? *Sexually Transmitted Infections*, 2003, 79:375–381.
29. Grosskurth H et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. *Lancet*, 1995, 346:530–536.
30. Manhart LE, Holmes KK. Randomized controlled trials of individual-level, population-level, and multilevel interventions for preventing sexually transmitted infections: what has worked? *Journal of Infectious Diseases*, 2005, 191(Suppl. 1):S7–S24.
31. Gilson L et al. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. *Lancet*, 1997, 350:1805–1809.
32. Creese A et al. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review. *Lancet*, 2002, 359:1635–1642.
33. Peeling R et al. Avoiding HIV and dying of syphilis. *Lancet*, 2004, 364:1561–1563.
34. Pagliusi SR, Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction. *Vaccine*, 2004, 23:569–578.
35. Harper DM et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. *Lancet*, 2004, 364:1757–1765.

36. Corey L et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. *JAMA*, 1999, 282:331–340.
37. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. *Bulletin of the World Health Organization*, 2004, 82:454–461.
38. *Population and Development, I: Programme of Action adopted at the International Conference on Population and Development, Cairo 5–13 September 1994*. New York, United Nations, Department for Economic and Social Information and Policy Analysis, 1995.
39. *Report of the Fourth World Conference on Women, Beijing, 4–15 September 1995*. New York, United Nations, 1995.
40. Shears KH. Family planning and HIV service integration, potential synergies are recognized. *Network*, 2004, 23:4–8.
41. Wasserheit JN, Aral SO. The dynamic typology of sexually transmitted disease epidemics: implications for prevention strategies. *Journal of Infectious Diseases*, 1996, 174(Suppl. 2):S201–S213.
42. May MM, Anderson RM. Transmission dynamics of HIV infection. *Nature*, 1987, 326:137–142.
43. Brunham RC, Plummer FA. A general model of sexually transmitted diseases and its implication for control. *The Medical Clinics of North America*, 1990, 74:1339–1352.
44. Blanchard JF. Populations, pathogens, and epidemic phases: closing the gap between theory and practice in the prevention of sexually transmitted diseases. *Sexually Transmitted Infections*, 2002, 78(Suppl. 1):i183–i188.
45. *Behavior change communication for HIV/AIDS*. Washington, DC, Family Health International, 2002.
46. *Intensifying HIV prevention: a UNAIDS policy position paper*. Joint United Nations Programme on HIV/AIDS, 2005 (UNAIDS/05.18E).
47. *Guidelines for the management of sexually transmitted infections*. Geneva, World Health Organization, 2003.
48. *The public health approach to STD control*. Geneva, World Health Organization and Joint United Nations Programme on HIV/AIDS, 1998 (UNAIDS Technical Update).
49. Dallabetta GA, Gerbase AC, Holmes KK. Problems, solutions, and challenges in syndromic management of sexually transmitted diseases. *Sexually Transmitted Infections*, 1998, 74(Suppl. 1):S1–S11.
50. Vuylsteke B. Current status of syndromic management of sexually transmitted infections in developing countries. *Sexually Transmitted Infections*, 2004, 80:333–334.
51. *Sexually transmitted diseases: policies and principles for prevention and care*. Geneva, Joint United Nations Programme on HIV/AIDS and World Health Organization, 1999 (UNAIDS/01.11E).
52. Golden MR et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. *New England Journal of Medicine*, 2005, 352:676–685.

53. Faxelid E et al. Individual counseling of patients with sexually transmitted diseases: a way to improve partner notification in a Zambian setting? *Sexually Transmitted Diseases*, 1996, 23:289-292.
54. *Guidelines for sexually transmitted infections surveillance*. Geneva, World Health Organization and Joint United Nations Programme on HIV/AIDS, 1999 (WHO/CHS/HSI/99.2; WHO/CDS/CSR/EDC/99.3; UNAIDS/99.33E).
55. *Guidelines for second generation HIV surveillance*. Geneva, Joint United Nations Programme on HIV/AIDS and World Health Organization, 2000 (UNAIDS/00.03E; WHO/CDS/CSR/EDC/2000.5).
56. Plummer FA et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. *Journal of Infectious Diseases*, 1991,163:233-239.
57. Cameron DW et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. *Lancet*, 1989, 2:403-407.
58. Laga M et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. *AIDS*, 1993, 7: 95-102.
59. Kassler WK et al. Seroconversion in patients attending sexually transmitted disease clinics. *AIDS*, 1994; 8: 351-55.
60. Craib KJ et al. Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. *Genitourinary Medicine*, 1995, Oct;71(5):335-6.
61. Telzak EE et al. HIV-1 seroconversion in patients with and without genital ulcer disease. A prospective study. *Annals of Internal Medicine*, 1993;119:1181-6.
62. Stamm WE et al. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. *The Journal of the American Medical Association*, 1988, 260:1429-1433.
63. Limpakarnjanarat K et al. HIV-1 and other sexually transmitted infections in a cohort of female sex workers in Chiang Rai, Thailand. *Sexually Transmitted Infections*, 1999, 75: 30-35.
64. Mbizvo MT et al. Trends in HIV-1 and HIV-2 prevalence and risk factors in pregnant women in Harare, Zimbabwe. *Central African Journal of Medicine*, 1996, Vol 42(1); 15-23.
65. Bollinger RC et al. Risk factors and clinical presentation of acute primary HIV infection in India. *The Journal of the American Medical Association*, 1997, 278:2085-2089.
66. Holmberg D et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. *The Journal of the American Medical Association*, 1988, 259:1048-1050.
67. Darrow WW et al. Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. *American Journal of Public Health*, 1987, 77:479-483.
68. *Safe abortion: technical and policy guidance for health systems*. Geneva, World Health Organization, 2003.
69. Mullick S et al. Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. *Sexually Transmitted Infections*, 2005, 81:294-302.

70. Taha TE et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. *AIDS*, 1998, 12:1699–1706.
71. *Iatrogenic infections of reproductive tract*. New York, Population Council, 2004 (Fact sheet, 1 July 2004).
72. Watson-Jones D et al. Syphilis in pregnancy in Tanzania II. The effectiveness of antenatal syphilis screening and single dose benzathine penicillin treatment for the prevention of adverse pregnancy outcomes. *Journal of Infectious Diseases*, 2002, 186:948–957.
73. *A picture of health? A review and annotated bibliography of the health of young people in developing countries*. Geneva, World Health Organization, 1995 (WHO/FHE/ADH/95.4).
74. *Programming for adolescent health and development. Report of a WHO/UNFPA/UNICEF Study Group on Programming for Adolescent Health*. Geneva, World Health Organization, 1999 (WHO Technical Report Series, No. 886).
75. Dehne KL, Riedner G. *Sexually transmitted infections among adolescents: the need for adequate health services*. Geneva, World Health Organization and Deutsche Gesellschaft für Technische Zusammenarbeit, 2005.
76. Brugha R, Zwi AB. Sexually transmitted disease control in developing countries: the challenge of involving the private sector. *Sexually Transmitted Infections*, 1999, 75:283–285.
77. Thomson O'Brien MA et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. *The Cochrane Database of Systematic Reviews*, 2001 (1:CD003030. DOI: 10.1002/14651858.CD003030).
78. Grosskurth H et al. Operational performance of an STD control programme in Mwanza Region, Tanzania. *Sexually Transmitted Infections*, 2000, 76:426–436.
79. *Selected topics in health reform and drug financing*. Geneva, World Health Organization, 1998.
80. Gray A. Drug Pricing. In: *South African health review 2000*. Durban, Health Systems Trust, 2000.
81. *The world health report 2000 – Health systems: improving performance*. Geneva, World Health Organization, 2000.
82. Ghys PD et al. Increase in condom use and decline in HIV and sexually transmitted diseases among female sex workers in Abidjan, Côte d'Ivoire, 1991–1998. *AIDS*, 2002, 16:251–258.
83. Mayaud P et al. Improved treatment services significantly reduce the prevalence of sexually transmitted diseases in rural Tanzania: results of a randomized controlled trial. *AIDS*, 1997, 11:1873–1880.
84. Kamali A et al. Syndromic management of sexually transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. *Lancet*, 2003, 361:645–652.
85. Htun Y et al. Comparison of clinically directed, disease specific, and syndromic protocols for the management of genital ulcer disease in Lesotho. *Sexually Transmitted Infections*, 1998, 74(Suppl. 1):S23–S28.

-
86. Chapel TA et al. How reliable is the morphological diagnosis of penile ulceration? *Sexually Transmitted Diseases*, 1977, 4:150–152.
 87. Dangor Y et al. Accuracy of clinical diagnosis of genital ulcer disease. *Sexually Transmitted Diseases*, 1990, 17:184–189.
 88. O’Farrell N et al. Genital ulcer disease: accuracy of clinical diagnosis and strategies to improve control in Durban, South Africa. *Genitourinary Medicine*, 1994, 70:7–11.
 89. Ndinya-Achola JO et al. Presumptive specific clinical diagnosis of genital ulcer disease (GUD) in a primary health care setting in Nairobi. *International Journal of STD and AIDS*, 1996, 7:201–205.
 90. Djajakusumah T et al. Evaluation of syndromic patient management algorithm for urethral discharge. *Sexually Transmitted Infections*, 1998, 74(Suppl. 1):S29–S33.
 91. Moherdaui F et al. Validation of national algorithms for the diagnosis of sexually transmitted diseases in Brazil: results from a multicentre study. *Sexually Transmitted Infections*, 1998, 74(Suppl. 1):S38–S43.
 92. Jha P et al. Reducing HIV transmission in developing countries. *Science*, 2001, 292:224–225.

= = =